[go: up one dir, main page]

FI970058L - A new oral pharmaceutical preparation containing the magnesium salt of omeprazole - Google Patents

A new oral pharmaceutical preparation containing the magnesium salt of omeprazole Download PDF

Info

Publication number
FI970058L
FI970058L FI970058A FI970058A FI970058L FI 970058 L FI970058 L FI 970058L FI 970058 A FI970058 A FI 970058A FI 970058 A FI970058 A FI 970058A FI 970058 L FI970058 L FI 970058L
Authority
FI
Finland
Prior art keywords
omeprazole
pharmaceutical preparation
magnesium salt
preparation containing
oral pharmaceutical
Prior art date
Application number
FI970058A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI970058A7 (en
FI970058A0 (en
Inventor
Siv Inga Bengtsson
Kurt Ingmar Loevgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of FI970058A7 publication Critical patent/FI970058A7/en
Publication of FI970058A0 publication Critical patent/FI970058A0/en
Publication of FI970058L publication Critical patent/FI970058L/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI970058A 1994-07-08 1995-07-03 A new oral pharmaceutical preparation containing the magnesium salt of omeprazole FI970058L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9400679 1994-07-08
PCT/SE1995/000816 WO1996001622A1 (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole

Publications (3)

Publication Number Publication Date
FI970058A7 FI970058A7 (en) 1997-01-07
FI970058A0 FI970058A0 (en) 1997-01-07
FI970058L true FI970058L (en) 1997-01-07

Family

ID=20393105

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970058A FI970058L (en) 1994-07-08 1995-07-03 A new oral pharmaceutical preparation containing the magnesium salt of omeprazole

Country Status (15)

Country Link
EP (1) EP0768872A1 (en)
KR (1) KR970704426A (en)
BR (1) BR9508261A (en)
CA (1) CA2193681A1 (en)
CZ (1) CZ379596A3 (en)
EE (1) EE03378B1 (en)
FI (1) FI970058L (en)
HU (1) HUT78132A (en)
IS (1) IS4398A (en)
MX (1) MX9700152A (en)
NO (1) NO970036D0 (en)
NZ (1) NZ289958A (en)
PL (1) PL181265B1 (en)
SK (1) SK281803B6 (en)
WO (1) WO1996001622A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5900258A (en) * 1996-02-01 1999-05-04 Zeolitics Inc. Anti-bacterial compositions
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704869D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9802973D0 (en) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
CA2413923A1 (en) * 2000-03-09 2001-09-13 Andrew Ilchyshyn Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1755566A2 (en) * 2004-06-15 2007-02-28 Teva Pharmaceutical Industries Ltd Stable pharmaceutical formulations of benzimidazole compounds
CN105106168B (en) * 2015-08-19 2018-03-06 德州德药制药有限公司 A kind of esomeprazole magnesium intestines capsule and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (en) * 1988-05-18 1995-07-26 エーザイ株式会社 Oral formulation of acid labile compounds
SE9302395D0 (en) * 1993-07-09 1993-07-09 Ab Astra NEW PHARMACEUTICAL FORMULATION
SE9302396D0 (en) * 1993-07-09 1993-07-09 Ab Astra A NOVEL COMPOUND FORM

Also Published As

Publication number Publication date
WO1996001622A1 (en) 1996-01-25
EP0768872A1 (en) 1997-04-23
HUT78132A (en) 2000-06-28
FI970058A7 (en) 1997-01-07
NO970036L (en) 1997-01-06
NO970036D0 (en) 1997-01-06
SK166096A3 (en) 1997-09-10
EE03378B1 (en) 2001-04-16
AU2994795A (en) 1996-02-09
BR9508261A (en) 1997-12-23
MX9700152A (en) 1997-04-30
WO1996001622A8 (en) 1999-12-23
KR970704426A (en) 1997-09-06
FI970058A0 (en) 1997-01-07
IS4398A (en) 1996-12-17
AU695723B2 (en) 1998-08-20
CZ379596A3 (en) 1997-08-13
SK281803B6 (en) 2001-08-06
EE9700014A (en) 1997-06-16
HU9700039D0 (en) 1997-02-28
PL181265B1 (en) 2001-06-29
CA2193681A1 (en) 1996-01-25
NZ289958A (en) 1998-09-24
PL318464A1 (en) 1997-06-09

Similar Documents

Publication Publication Date Title
EE9600118A (en) New oral pharmaceutical dosage form
ATE206924T1 (en) ORAL MEDICINAL PREPARATION CONTAINING OLNZAPINE
EE200000395A (en) Oral pharmaceutical pulsatile dosage form
FI970058L (en) A new oral pharmaceutical preparation containing the magnesium salt of omeprazole
DK0936913T4 (en) ORAL PHARMACEUTICAL PREPARATION CONTAINING IBANDRONATE
EE200000383A (en) Oral pharmaceutical extended release dosage form
FI964682L (en) Pharmaceutical preparation containing glucagon
FI970995L (en) Pharmaceutical compounds
FI971018L (en) Pharmaceutical compounds
FI954243A7 (en) Pharmaceutical compounds
FI910088L (en) ORAL PHARMACEUTICAL COMPOSITION.
DK290989A (en) PHARMACEUTICAL PREPARATION AGAINST NEPHRITIS
NO975680L (en) Oral pharmaceutical preparation of piperidinoalkanol compounds in solution form
FI951155A7 (en) Pharmaceutical preparation
FI964918L (en) Pharmaceutical salts
EE200000401A (en) Process for the preparation of a pharmaceutical preparation
FI903885A0 (en) NY ORAL PHARMACEUTICAL DOSERINGSFORM SOM FOERBAETTRAR BIOTILLGAENGLIGHETEN.
SE9402433D0 (en) New oral pharmaceutical dosage form
NL193607B (en) Pharmaceutical preparation containing N-acetylcysteine.
NO20003284D0 (en) Pharmaceutical preparation for oral administration
SE9402432D0 (en) New pharmaceutical dosage form
SE9402925D0 (en) Novel oral pharmaceutical composition
ZA917309B (en) New oral drug forms
NO962816D0 (en) Pharmaceutical compounds
HK1008297A (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole